Compare Stocks: MCRB, BNR, RNA, and MOLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.07 -8.4%	$10.46	$6.79 ▼ $41.72	$173.02M	1.38	52,729 shs	24,078 shs
MCRB Seres Therapeutics	$3.79 -5.7%	$4.86	$3.73 ▼ $29.98	$40.38M	0.21	49,329 shs	51,646 shs
MOLN Molecular Partners	$4.30 +0.9%	$4.17	$3.53 ▼ $5.36	$172M	1.09	1,490 shs	286 shs
RNA Avidity Biosciences	$8.33 -9.7%	$11.98	$8.29 ▼ $16.77	$157.71M	N/A	371,333 shs	433,957 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-8.39%	+20.37%	+52.01%	+89.56%	+64.16%
MCRB Seres Therapeutics	-5.72%	-9.98%	-18.67%	-44.59%	-78.42%
MOLN Molecular Partners	+0.94%	+9.53%	-2.27%	+9.41%	+14.51%
RNA Avidity Biosciences	-9.65%	-12.32%	-38.84%	-34.82%	-80.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.07 -8.4%	$10.46	$6.79 ▼ $41.72	$173.02M	1.38	52,729 shs	24,078 shs
MCRB Seres Therapeutics	$3.79 -5.7%	$4.86	$3.73 ▼ $29.98	$40.38M	0.21	49,329 shs	51,646 shs
MOLN Molecular Partners	$4.30 +0.9%	$4.17	$3.53 ▼ $5.36	$172M	1.09	1,490 shs	286 shs
RNA Avidity Biosciences	$8.33 -9.7%	$11.98	$8.29 ▼ $16.77	$157.71M	N/A	371,333 shs	433,957 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-8.39%	+20.37%	+52.01%	+89.56%	+64.16%
MCRB Seres Therapeutics	-5.72%	-9.98%	-18.67%	-44.59%	-78.42%
MOLN Molecular Partners	+0.94%	+9.53%	-2.27%	+9.41%	+14.51%
RNA Avidity Biosciences	-9.65%	-12.32%	-38.84%	-34.82%	-80.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
MCRB Seres Therapeutics	2.25	Hold	$17.00	348.55% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	94.77% Upside
RNA Avidity Biosciences	2.25	Hold	$63.75	665.31% Upside

Current Analyst Ratings Breakdown

Latest MCRB, BNR, RNA, and MOLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$514.43M	0.31	N/A	N/A	$7.28 per share	2.07
MCRB Seres Therapeutics	$790K	48.21	$1.02 per share	3.70	$4.89 per share	0.78
MOLN Molecular Partners	$5.65M	30.73	N/A	N/A	$2.40 per share	1.79
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.71	N/A	N/A	N/A	N/A	-68.36%	-54.82%	10/29/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)

Latest MCRB, BNR, RNA, and MOLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.44	+$0.01	-$0.43	N/A	N/A
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
MCRB Seres Therapeutics	N/A	2.11	2.11
MOLN Molecular Partners	N/A	7.27	7.27
RNA Avidity Biosciences	N/A	8.73	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
MCRB Seres Therapeutics	59.34%
MOLN Molecular Partners	26.55%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
MCRB Seres Therapeutics	5.20%
MOLN Molecular Partners	5.93%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
MCRB Seres Therapeutics	66	10.05 million	9.52 million	Optionable
MOLN Molecular Partners	134	40.38 million	37.98 million	Not Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable

MCRB, BNR, RNA, and MOLN Headlines

Recent News About These Companies

Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Target Price at $63.75

3 hours ago | americanbankingnews.com

Avidity Biosciences stock leaves Nasdaq after Novartis deal

September 23 at 12:13 AM | ad-hoc-news.deA

Avidity Biosciences stock gains 4.79 percent as RNA trades at USD 9.18

September 22 at 3:07 AM | ad-hoc-news.deA

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 21 at 4:30 PM | prnewswire.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Hold" by Brokerages

September 19, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Share Price Passes Below Two Hundred Day Moving Average - Here's Why

September 18, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?

September 10, 2026 | marketbeat.com

Novartis RNA drug falls short in rare muscle disease study

September 9, 2026 | finance.yahoo.com

Novartis’ $12B Avidity bet suffers Phase 3 blow

September 8, 2026 | european-biotechnology.comE

Atrium Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below 200 Day Moving Average - Time to Sell?

September 2, 2026 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts

August 25, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026 | prnewswire.com

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

August 13, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | prnewswire.com

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026 | prnewswire.com

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

June 14, 2026 | finance.yahoo.com

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

June 12, 2026 | biopharmadive.comB

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MCRB, BNR, RNA, and MOLN Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$15.07 -1.38 (-8.39%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$15.16 +0.09 (+0.60%)

As of 04:08 AM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Seres Therapeutics NASDAQ:MCRB

$3.79 -0.23 (-5.72%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.11 (+2.90%)

As of 05:52 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Molecular Partners NASDAQ:MOLN

$4.30 +0.04 (+0.94%)

Closing price 09/23/2026 03:08 PM Eastern

Extended Trading

$4.04 -0.26 (-6.14%)

As of 04:12 AM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Avidity Biosciences NASDAQ:RNA

$8.33 -0.89 (-9.65%)

As of 09/23/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, BNR, RNA, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, BNR, RNA, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, BNR, RNA, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MCRB, BNR, RNA, and MOLN Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Seres Therapeutics NASDAQ:MCRB

Molecular Partners NASDAQ:MOLN

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, BNR, RNA, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, BNR, RNA, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, BNR, RNA, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MCRB, BNR, RNA, and MOLN Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Seres Therapeutics NASDAQ:MCRB

Molecular Partners NASDAQ:MOLN

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools